Engineering siRNA therapeutics: challenges and strategies

Area of Science:

• Molecular Biology
• Biotechnology
• Pharmacology

Background:

• Small interfering RNA (siRNA) is a potent gene silencing tool with approved therapeutics by the FDA.
• Significant biological barriers impede the clinical application of siRNA therapeutics, limiting their efficacy.
• These barriers include administration challenges, short half-life, degradation, immune responses, and poor cellular uptake.

Purpose of the Study:

• To review and summarize strategies for overcoming biological barriers in siRNA delivery.
• To highlight advancements in stabilizing siRNA and enhancing its therapeutic potential.

Main Methods:

• Chemical modifications of nucleotides and phosphate backbones to reduce off-target effects and immunogenicity.
• Encapsulation and formulation techniques to protect siRNA from degradation and improve cellular uptake.
• Development of diverse delivery systems including viral vectors, aptamers, peptides, liposomes, and polymers.

Main Results:

• Chemical modifications effectively decrease off-target binding and immune stimulation.
• Formulation strategies protect siRNA from degradation, enhance cellular uptake, and promote endosomal escape.
• Advanced delivery systems significantly improve siRNA bioavailability and therapeutic outcomes.

Conclusions:

• Overcoming biological barriers is crucial for realizing the full therapeutic potential of siRNA.
• A combination of chemical modifications and sophisticated delivery systems represents a promising approach for effective siRNA-based therapies.
• Continued innovation in siRNA delivery is vital for advancing treatments for various diseases.